Abstracts tagged "Outcome measures"

Abstract Number: 1972 • ACR Convergence 2025
Enhancing Patient Safety: Improving Contraceptive Counseling for Patients on Teratogenic Medications in the Rheumatology Clinic
Abimbola Fadairo-Azinge¹, jobelle Romulo², Daniella Flores³, jose Giron², Joshua Ng⁴, Sarah Patterson⁵, Jinoos Yazdany⁶ and Andrew Gross⁶, ¹UCSF, San Francisco, ²University of California San Francisco, San Francisco, ³University of California San Francisco, San Francisco, CA, ⁴University of California San Francisco, SAN-FRANCISCO, CA, ⁵University of California, San Francisco, Pacifica, CA, ⁶UCSF, San Francisco, CA
Background/Purpose: The American College of Rheumatology (ACR) recommends contraceptive counseling for reproductive-age women with rheumatic and musculoskeletal diseases (RMDs), especially those on teratogenic medications. These…
Abstract Number: 1493 • ACR Convergence 2025
Long-Term Outcomes in Systemic Lupus Erythematosus Patients Infected with SARS-CoV-2: Variant-Specific Analysis of Pre-Delta/Delta and Omicron Periods
Lilliana Serrano-Arroyo, César Rosado-Bloise and Luis Vilá, University of Puerto Rico Medical Sciences Campus, San Juan, PR
Background/Purpose: The post-acute sequelae of SARS-CoV-2 infection may involve low-grade inflammation, immune dysregulation, and endothelial dysfunction. Therefore, it would not be surprising if SARS-CoV-2 negatively…
Abstract Number: 1255 • ACR Convergence 2025
Lung Transplantation Outcomes for Pulmonary Sarcoidosis Compared to Idiopathic Pulmonary Fibrosis: A Single Institution Multisite Experience
Reena Yaman¹, Lisa Balistreri², Maximiliano Diaz Menindez³, Sehreen Mumtaz¹, Megan Sullivan³, Alexander Hochwald¹ and Florentina Berianu¹, ¹Mayo Clinic Florida, Jacksonville, FL, ²Lee Health, Cape Coral, FL, ³Mayo Clinic Arizona, Scottsdale, AZ
Background/Purpose: Pulmonary disease is present in most sarcoidosis cases with up to 10% of patients progressing to advanced lung disease.1 Pulmonary sarcoidosis accounted for 2.5%…
Abstract Number: 0691 • ACR Convergence 2025
Association of Elevated Platelets and CRP With Severe Disease and Poor Survival in Systemic Sclerosis
Brian Lee¹, Shufeng Li¹, Srijana Davuluri², Jennifer Lee¹ and Lorinda Chung², ¹Stanford University, Stanford, ²Stanford University, Stanford, CA
Background/Purpose: Elevated acute phase reactants such as platelets and C-reactive protein (CRP) have been used as inclusion criteria to enrich systemic sclerosis (SSc) clinical trials…
Abstract Number: 0539 • ACR Convergence 2025
Which instrument measuring structural damage progression in axial SpA is most sensitive to change? Analyses from the SPondyloArthritis Caught Early cohort
Liese de Bruin¹, Floris A. van Gaalen¹, Manouk de Hooge², Miranda van Lunteren¹, Mary Lucy Marques³, Monique Reijnierse⁴, Roberta Ramonda⁵, Inger Jorid Berg⁶, Sofia Exarchou⁷, Robert Landewé⁸, Désirée Van Der Heijde¹ and Sofia Ramiro⁹, ¹Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Department of Rheumatology, Ghent University Hospital, Ghent, Belgium, ³Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands; and Coimbra Local Health Unit, Coimbra, Portugal, ⁴Department of Radiology, Leiden University Medical Center, Leiden, Netherlands, ⁵Rheumatology Unit-DIMED-University of Padova ITALY, Padova, Padua, Italy, ⁶⁶Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Nepal, ⁷Lund University, Åkarp, Skane Lan, Sweden, ⁸Department of Rheumatology, Amsterdam University Medical Center, Amsterdam, Netherlands; and Zuyderland Medical Center, Heerlen, Netherlands, ⁹Leiden University Medical Center, Bunde, Netherlands
Background/Purpose: The assessment of structural damage progression is an important part of outcome assessment in axial SpA (axSpA). In order to test whether interventions can…
Abstract Number: 0313 • ACR Convergence 2025
People with Knee Osteoarthritis Infrequently Seek Medical Care for Arthritis, Even Those With Severe Disease
Grace Lo¹, Shunshun Yan², Julieann Patarini³, Timothy McAlington⁴, Charles Eaton⁵ and Jeffrey Driban⁶, ¹Baylor College of Medicine / MEDVAMC, Houston, TX, ²Baylor College of Medicine, Houston, ³UMass Chan Medical School, Worcester, MA, ⁴UMass Chan School of Medicine, Arlington, MA, ⁵Brown University, Providence, RI, ⁶University of Massachusetts Chan Medical School, Marlborough, NH
Background/Purpose: Osteoarthritis (OA) is the most common form of arthritis, a condition associated with substantial disability. Providers are often uncomfortable managing arthritis, and patients with…
Abstract Number: L10 • ACR Convergence 2024
Neuroimmune Modulation in Adults with Rheumatoid Arthritis and Inadequate Response or Intolerance to Biological or Targeted Synthetic DMARDs: Results at 12 and 24 Weeks from a Randomized, Sham-Controlled, Double-Blind Pivotal Study
John Tesser¹, Joshua June², Pendleton Wickersham³, Jane Box⁴, Guillermo Valenzuela⁵, Angela Crowley⁶, Nikila Kumar⁷, Norman Gaylis⁸, Gordan Lam⁹, David Ridley¹⁰, Gineth Paola Pinto-Patarroyo¹¹ and David Chernoff¹², ¹Arizona Arthritis & Rheumatology Associates, Phoenix, AZ, ²Great Lakes Center of Rheumatology, Lansing, MI, ³Arthritis Associates PA, San Antonio, TX, ⁴DJL Clinical Research, PLLC, Charlotte, NC, ⁵Guillermo Valenzuela MD PA/ IRIS Rheumatology, Plantation, FL, ⁶Illinois Bone and Joint Institute - Hinsdale Orthopaedics, Hinsdale, IL, ⁷Arizona Arthritis & Rheumatology Associates, Scottsdale, AZ, ⁸Arthritis & Rheumatic Disease Specialties, Aventura, FL, ⁹Arthritis & Osteoporosis Consults of the Carolinas, Charlotte, NC, ¹⁰St. Paul Rheumatology, Eagan, MN, ¹¹Annapolis Rheumatology, Fairfax, VA, ¹²SetPoint Medical, Sausalito, CA
Background/Purpose: In this study, we evaluated the safety and efficacy of an implantable, cervical vagus nerve stimulation device for treatment of RA. Methods: This randomized,…
Abstract Number: 0132 • ACR Convergence 2024
Patients with Systemic Autoimmune Rheumatic Diseases Remain at Risk for Hospitalization for COVID-19 Infection in the Omicron Era (2022-2024): A Retrospective Cohort Study
Naomi Patel¹, Andrew King¹, Shruthi Srivatsan¹, Xiaosong Wang², Emily Kowalski³, Kathleen Vanni³, Grace Qian², Jennifer Hanberg³, Katarina Bade³, Alene Saavedra³, Kevin Mueller³, Zachary Williams¹, Colebrook Johnson¹, Madison Negron¹, Jeffrey Sparks⁴ and Zachary Wallace⁵, ¹Massachusetts General Hospital, Boston, MA, ²Brigham and Women’s Hospital, Boston, MA, ³Brigham and Women's Hospital, Boston, MA, ⁴Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA, Boston, MA, ⁵Massachusetts General Hospital, Newton, MA
Background/Purpose: The risk of severe acute COVID-19 infection has substantially decreased since the start of the pandemic. However, the risk of severe acute COVID-19 outcomes…
Abstract Number: 0361 • ACR Convergence 2024
Maternal and Fetal Outcomes in Those with Autoimmune Connective Tissue Disease
Nada Alrifai¹, Anushree Puttur², Laith Alhuneafat³, Fares Ghanem⁴, yadhu Dhital², Ahmad Jabri⁵ and David Feinstein⁶, ¹Cooper University Hospital, Cherry Hill, NJ, ²Allegheny Health Network, Pittsburgh, PA, ³University of Minnesota, Minneapolis, MN, ⁴Southern Illinois University, Springfield, IL, ⁵Henry Ford, Detroit, MI, ⁶Cooper University, Camden, NJ
Background/Purpose: Autoimmune connective tissue diseases (CTD) predominantly affect women during their reproductive years. CTDs such as systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and systemic…
Abstract Number: 0586 • ACR Convergence 2024
Real World Effectiveness of Upadacitinib in Patients with Psoriatic Arthritis Previously Treated with TNF Inhibitors: Data from the OM1 Registry
Alexis Ogdie¹, Xiaolan Ye², Yi Peng³, Christopher Saffore⁴, Jayne Stigler⁵ and Martin Bergman⁶, ¹Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ²AbbVie Inc., Mettawa, IL, ³AbbVie Inc, North Chicago, IL, ⁴AbbVie Inc., waukegan, IL, ⁵AbbVie Inc., North Chicago, IL, ⁶self, Beach Haven, NJ

Background/Purpose: Upadacitinib (UPA), an oral JAK inhibitor, has demonstrated efficacy for the treatment of PsA in randomized controlled trials of patients with inadequate response or…
Abstract Number: 0708 • ACR Convergence 2024
Outcomes of Intermittent Intravenous Steroid Use During Infusion Therapy in Systemic Sclerosis
Vangala Adarsh¹, dihowm Fatma¹, Eyerusalem Akpan², Meredith Keller², Maheswari Muruganandam², N. Suzanne Emil², Frank O'Sullivan³, Roderick Fields² and wilmer sibbitt¹, ¹UNM, Albuquerque, NM, ²University of New Mexico, Albuquerque, NM, ³University of New Mexico School of Medicine, Albuquerque, NM
Background/Purpose: Use of high dose corticosteroids in systemic sclerosis (SSc) is considered a significant risk factor for development of scleroderma renal crisis (SRC). Intravenous (IV)…
Abstract Number: 1032 • ACR Convergence 2024
Impact of a Coordinated Care Model for Addressing Rheumatoid Arthritis and Associated Comorbidities
Alexis Barbut¹, Marsha Jackson², Krista Kowiak², Julie McIntyre² and Allen Anandarajah¹, ¹University of Rochester Medical Center, Rochester, NY, ²University of Rochester Medical Center, Rochester
Background/Purpose: Rheumatoid Arthritis (RA) is often associated with comorbidities including hypertension, cardiovascular disease, osteoporosis, lung disease, and eye involvement. Studies suggests that the average RA…
Abstract Number: 1341 • ACR Convergence 2024
Evaluation of Width Range Index (WRI) and Neutrophil-to-Lymphocyte Ratio (NLR) in Assessing Disease Activity in Patients with Rheumatoid Arthritis
Santiago Dans Caballero¹, Marta Rojas Giménez², Clementina López Medina³, Andrea Cid Chaves², Mónica Rico-Muñoz³, mitndbaim aelohim parra Moreno² and Alejandro Escudero-Contreras⁴, ¹Reina Sofia University Hospital, Lebrija, Andalucia, Spain, ²Reina Sofia University Hospital, Cordoba, Andalucia, Spain, ³Reina Sofia University Hospital, Cordoba, Spain, ⁴Reina Sofia University Hospital, Córdoba, Spain
Background/Purpose: Rheumatoid arthritis (RA) is a chronic inflammatory condition characterized by joint inflammation and systemic involvement. In this preliminary study, we explore the potential link…
Abstract Number: 1581 • ACR Convergence 2024
Neutrophil-to- lymphocyte Ratio: A Possible Biomarker for Clinical Response After Autologous Hematopoietic Stem Cell Transplantation
shiri keret¹, Lisa Kaly², Georg Schett³, Christina Bergmann⁴, Joerg Henes⁵, Gleb Slobodin² and Doron Rimar², ¹Rheumatology unit, Bnai-Zion medical center and the faculty of Medicine, Technion - Israel Institute of Technology, Haifa, Israel., Atlit, Israel, ²Rheumatology unit, Bnai-Zion medical center and the faculty of Medicine, Technion - Israel Institute of Technology, Haifa, Israel., Haifa, Israel, ³Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany, ⁴Department Internal Medicine III, Friedrich-Alexander-University (FAU) Erlangen-Nurnber, Frankfurt, Germany, ⁵University Hospital Tuebingen, Tuebingen, Germany
Background/Purpose: Baseline high Neutrophil- to- lymphocyte ratio (NLR) (higher than 2.95) is associated with severe progressive skin and lung disease and with reduced 5-year survival…
Abstract Number: 2087 • ACR Convergence 2024
Association of MRI-Defined Structure Features at Baseline with Knee Pain and Function Trajectories: Data from the Osteoarthritis Initiative (OAI)
Shen Liu¹, Thang Doung², Yong Ge³, Xiaoxiao Sun⁴, Yvonne Golightly⁵, Amanda Nelson⁶, Tuhina Neogi⁷, Jeffery Duryea⁸ and Kent Kwoh⁹, and Osteoarthritis Initiative (OAI) and Pivotal Osteoarthritis MRI Analyses (POMA) investigators, ¹Department of Biostatistics, Mel and Enid Zuckerman College of Public Health, University of Arizona, Tucson, AZ, ²Department of Computer Science, University of Arizona College of Science, Tucson, AZ, ³Department of Information Sciences, Eller College of Manangement, University of Arizona, Tucson, AZ, ⁴Department of Biostatistics, Mel and Enid Zuckerman College of Public Health, University of Arizona, Tucson, AZ, ⁵University of Nebraska Medical Center, Omaha, NE, ⁶University of North Carolina at Chapel Hill, Chapel Hill, NC, ⁷Boston University Chobanian & Avedisian School of Medicine, Boston, MA, ⁸Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁹University of Arizona, Tucson, AZ
Background/Purpose: Characterizing knee symptom (i.e., pain and function) trajectories and understanding differences among symptom trajectories have the potential to promote the development of customized treatment…

« Previous Page
1
…
8
9
10
11
12
…
59
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].